The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Sunitinib: From Rational Design to Clinical Efficacy
Abstract
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and SU5416 (semaxanib) demonstrated poor pharmacologic properties and limited efficacy; therefore, sunitinib was rationally designed and chosen for its high bioavailability and its nanomolar-range potency against the antiangiogenic receptor tyrosine kinases (RTKs)—vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Sunitinib inhibits other tyrosine kinases including, KIT, FLT3, colony-stimulating factor 1 (CSF-1), and RET, which are involved in a number of malignancies including small-cell lung cancer, GI stromal tumors (GISTs), breast cancer, acute myelogenous leukemia, multiple endocrine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma. Sunitinib demonstrated robust antitumor activity in preclinical studies resulting not only in tumor growth inhibition, but tumor regression in models of colon cancer, non–small-cell lung cancer, melanoma, renal carcinoma, and squamous cell carcinoma, which were associated with inhibition of VEGFR and PDGFR phosphorylation. Clinical activity was demonstrated in neuroendocrine, colon, and breast cancers in phase II studies, whereas definitive efficacy has been demonstrated in advanced renal cell carcinoma and in imatinib-refractory GISTs, leading to US Food and Drug Administration approval of sunitinib for treatment of these two diseases. Studies investigating sunitinib alone in various tumor types and in combination with chemotherapy are ongoing. The clinical benchmarking of this small-molecule inhibitor of members of the split-kinase domain family of RTKs will lead to additional insights regarding the biology, potential biomarkers, and clinical utility of agents that target multiple signaling pathways in tumor, stromal, and endothelial compartments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rini, B. I., Sosman, J. A., & Motzer, R. J. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05616.x · Cited by 51
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Cited by
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., Derweesh, I. H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0001 · Cited by 667
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0664-7 · Cited by 658
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Bhayani, S., Bro, W. P., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Fishman, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0100 · Cited by 571
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504
Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477
Motzer, R. J., Agarwal, N., Beard, C., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S. L., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0043 · Cited by 470
Carr, L. L., Mankoff, D. A., Goulart, B. H., Eaton, K. D., Capell, P. T., Kell, E. M., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393
Yeung, T.-L., Leung, C. S., Yip, K.-P., Au Yeung, C. L., Wong, S. T. C., & Mok, S. C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2015 · Cited by 377
Harris, P. A., Boloor, A., Cheung, M., Kumar, R., Crosby, R. M., Davis-Ward, R. G., Epperly, A. H., Hinkle, K. W., Hunter, R. N., Johnson, J. H., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800566m · Cited by 352
George, S., Merriam, P., Maki, R. G., Van den Abbeele, A. D., Yap, J. T., Akhurst, T., Harmon, D. C., Bhuchar, G., O'Mara, M. M., D'Adamo, D. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9890 · Cited by 321
Motzer, R. J., Hutson, T. E., Olsen, M. R., Hudes, G. R., Burke, J. M., Edenfield, W. J., Wilding, G., Agarwal, N., Thompson, J. A., Cella, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4133 · Cited by 275
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Anticancer strategies involving the vasculature
Heath, V. L., & Bicknell, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.52 · Cited by 255
Fibroblast growth factor (FGF) signaling in development and skeletal diseases
Teven, C. M., Farina, E. M., Rivas, J., & Reid, R. R. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.09.005 · Cited by 237
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Bex, M., Carmeliet, P., & Schöffski, P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604497 · Cited by 198
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial
Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58
Fuchs, K., Kiss, A., Bize, P. E., Duran, R., Denys, A., Hopfgartner, G., Borchard, G., & Jordan, O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.042 · Cited by 21
Metadata
- Authors
- Chow, L. Q. M., & Eckhardt, S. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-03-01
- Volume
- 25
- Issue
- 7
- Pages
- 884-896
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153331460
- Cited by
- 883
- References
- 60
- FWCI
- 28.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.